Enterome, a gut healthcare company backed by Natixis venture unit Seventure, raises the funds after a $1.5m seed round from Inra Transfert, the French National Institute in Agronomic Research's tech transfer organisation.
Enterome, a company focused on diseases of the gut, has raised €5m ($6.6m).
The company’s series A was co-led by Seventure, part of France-based bank Natixis, and venture firm Lundbeckfond Ventures.
It previously raised €1.5m from Seventure Partners and Inra Transfert, the French National Institute in Agronomic Research’s tech transfer organisation.
Gérard Jacquin, president of Inra Technology Transfer organisation, said: "We are particularly pleased to see one of our main research assets being translated into a company and financed by an international group of investors. Enterome is a key element in our Metagenopolis organization, a centre for excellence in metagenomics of the human gut microbiota developed at Inra."
Isabelle de Cremoux, chief executive of Seventure, said: "I am particularly proud to see Enterome developing, helped by the strong and longstanding relationship Seventure has established with INRA."
Johan Kördel, from Lundbeckfond Ventures, said: "We are impressed by the Enterome leadership and are very confident that Enterome will translate this very innovative platform into valuable diagnostic and therapeutic tools."
Emmanuelle Porte and Sylvie Hamel, from law firm Nixon Peabody, advised Enterome.
